Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.
Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.
Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.
Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.
Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.
For more information, visit the company's website at www.cellectis.com.
Cellectis, a clinical-stage biotechnology company, specializes in gene-editing for cancer therapies. As of February 28, 2022, the company has a total of 45,484,310 shares in capital and 51,076,931 voting rights. Utilizing its TALEN® technology and PulseAgile system, Cellectis aims to develop allogeneic CAR-T immunotherapies for various cancers, including AML and B-ALL. The company is committed to addressing unmet medical needs in oncology and blood disorders.
Cellectis (Nasdaq: CLLS) reported its fourth quarter and full-year 2021 results, highlighting a consolidated cash position of $191 million as of December 31, 2021, down from $274 million in 2020. The company experienced a consolidated revenue decrease to $67 million from $82 million in 2020. R&D expenses rose significantly to $129 million from $87 million. Cellectis presented encouraging preliminary results for its BALLI-01 study of UCART22 at ASH 2021, with plans for an IND submission for UCART20x22 in 2022. A conference call is scheduled for March 4, 2022, to discuss results.
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biotechnology firm specializing in gene editing, will announce its financial results for the fourth quarter and the year-end 2021 on March 3, 2022, after market closure. This will be followed by a conference call on March 4, 2022, at 8:00 AM EDT, detailing its quarterly and annual results and business updates. Cellectis focuses on innovative cell and gene therapies for cancer and blood disorders, utilizing its TALEN® technology and PulseAgile electroporation system.
Cellectis, a clinical-stage biotechnology company focused on gene editing, announced an underwritten offering to an institutional investor involving Calyxt, its majority-owned subsidiary. The offering includes 3,880,000 shares of Calyxt common stock, pre-funded warrants for 3,880,000 shares, and common warrants for 7,760,000 shares, all priced at $1.41 each. As of December 31, 2021, Calyxt reported cash and cash equivalents of $13.7 million and total current liabilities of $4.1 million. The preliminary financial data is subject to audits and potential adjustments.
Cellectis, a clinical-stage biotechnology company, focuses on gene editing and cell therapies for cancer treatment. As of January 31, 2022, the total number of shares outstanding is 45,484,310, with 51,085,785 voting rights. The company aims to provide lifesaving UCART products targeting multiple cancers and has developed a new platform, .HEAL, for treating blood disorders. Cellectis strives to leverage its TALEN® technology and PulseAgile system for innovative therapies. It is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis has appointed Bing C. Wang, PhD, MBA, as the new Chief Financial Officer. Wang brings extensive experience in biotechnology finance, previously serving as CEO of Refuge Biotechnologies and in investment banking with Barclays and Citigroup. He will manage Cellectis’ global finance team, aiming to enhance the company’s financial strategy during its clinical trial developments. Wang's background includes strategic capital raising and corporate finance, making him a valuable addition to Cellectis as it focuses on developing off-the-shelf cancer therapies.
Cellectis announced its share and voting rights status as of December 31, 2021. The total number of shares in capital stood at 45,484,810, while the total number of voting rights reached 51,085,782. The company specializes in gene editing and is known for its innovative CAR-T immunotherapies aimed at treating various cancers, including acute myeloid leukemia and multiple myeloma. Cellectis operates from its headquarters in Paris and has a presence in New York and North Carolina. Its commitment to developing life-saving therapies positions it as a leader in the biotech sector.
Cellectis (Nasdaq: CLLS) reported that the FDA has lifted the clinical hold on its partner Allogene Therapeutics’ clinical trials, enabling the resumption of studies for ALLO-501A, an anti-CD19 CAR-T cell therapy. This decision follows investigations revealing that a chromosomal abnormality found in a single patient was unrelated to TALEN® gene editing or Allogene’s manufacturing process. The abnormality's clinical significance was deemed negligible.
Allogene plans to start a pivotal Phase 2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma by mid-2022.
Cellectis (Nasdaq: CLLS) announced its 2022 business objectives, focusing on ongoing clinical trials BALLI-01, AMELI-01, and MELANI-01. The company aims to enroll patients in these trials and file an IND for UCART20x22, its first dual allogeneic CAR-T product. Cellectis has operational manufacturing sites in Raleigh and Paris, projecting its cash runway into early 2024 with $201 million available as of September 30, 2021. The company is committed to advancing its pipeline of life-saving cell and gene therapies.
Cellectis announced preliminary results from the BALLI-01 Phase 1 study of UCART22, targeting relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study demonstrated that UCART22 can be administered safely after lymphodepletion with FCA, showing no dose-limiting toxicities. Encouraging anti-leukemic activity was observed in 2 out of 6 patients, with one achieving blast reduction to 0%. The trial is currently enrolling at dose level 3. Additionally, preclinical data for TALGlobin01 showed efficient correction of the mutated beta-globulin gene for sickle cell disease.
FAQ
What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?
What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?
What does Cellectis S.A. specialize in?
What proprietary technologies does Cellectis use?
What are UCART cells?
What recent advancements has Cellectis made?
Which companies has Cellectis partnered with?
On which stock markets is Cellectis listed?
What are HSPCs?
How long has Cellectis been in the gene editing field?
Where can I find more information about Cellectis?
How does Cellectis contribute to immuno-oncology?
